|
| Study | Study design | Sample | Measures | Main findings | Critique |
|
| Forton et al. [22]. (2002) | Cross-sectional | HCV: 27
HCV/PCR-: 16 | D.C.R/T.T/C.T | Worst performance in the HCV group | Inclusion of depressed patients |
|
| Hilsabeck et al. [26] (2002) | Cross-sectional | HCV: 66
Hepatopathy of another cause: 14 | R.C.F/D.C.T/T.T/C.T | No difference between the groups | Inclusion of patients with liver cirrhosis |
|
| Kramer et al. [29]. (2002) | Cross-sectional | HCV: 100
Group control: 100 | P300
Minimental | Increased latency and reduced P300 amplitude in the group HCV | Inclusion of patients with liver cirrhosis |
|
| Córdoba et al. [28] (2004) | Cross-sectional | HCV: 40
HCV cirrhosis: 40
HCV D.C: 40
Group control: 40 | A.V.L.T/T.T/C.T
S.T/P.G/H.T | No difference between the groups | Inclusion of patients with liver cirrhosis |
|
| Weissenborn et al. [30] (2004) | Cross-sectional | HCV M.F: 15
HCV Moderate F: 15
Group control: 15 | R.C.F/figure
L.W.L.T/C.T | Worst cognitive performance of patients with HCV in cognitive fields involving attention and executive function | Inclusion of depressed patients |
|
| McAndrews et al. [24] (2005) | Cross-sectional | HCV: 37
Group control: 46 | T.D/C.T/T.T
S.T/S.T.W | Worst performance in the HCV group | Advanced hepatic fibrosis |
|
| Weissenborn et al. [31] (2006) | Cross-sectional | HCV: 16
HCV/PCR-: 4 | Test d2
Battery tap | Cognitive change in 2/3 of individuals involving attention/concentration in the HCV group | High score in BDI |
|
| Karaivazglou et al. [27]. (2007) | Cross-sectional | HCV: 32
HBV: 29
Group control: 20 | RAVLT/S.F.T
T.T/C.T | No difference between the groups | Inclusion of patients with liver cirrhosis |
|
| Forton et al. [32]. (2008) | Cross-sectional | HCV: 16
HCV/PCR-: 18
Group control: 85-420 | D.C.R | Change in the HCV + PCR + group involving working memory and attention when compared to the control and when compared to the HCV + PCR group | History of use of illicit drugs |
|
| Huckans et al. [33]. (2009) | Cross-sectional | HCV: 39 H.U.A.ID
HCV: 24 N.H.A.ID
Group control: 56 | T.F.V/T.R.C.F/C.T/T.T | Cognitive change: attention, verbal memory, and psychomotor speed in the HCV group independent from the use of substances | Inclusion of depressed patients |
|
| Quarantini et al. [34]. (2009) | Cross-sectional | HCV: 33
HBV: 22 | T.R.C.F/RAVLT; T.D; T.T | Worst performance of the HCV group in immediate memory in relation to the HBV group | Potential inclusion of patients with liver cirrhosis |
|
| Lowry et al. [35]. (2010) | Cross-sectional | HCV: 11
HCV PCR-: 9
Group control: 9 | WMS III | The HCV group presented worst scores of memory and attention when compared to the control group | Inclusion of depressed patients |
|
| Farag et al. [36]. (2011) | Cross-sectional | HCV: 11
Group control: 14 | W.C.T | The HCV group presented the worst results in the executive function tests and increase in the soluble receiver ii of the necrosis factor | Inclusion of patients with liver cirrhosis |
|
| Abrantes et al. [25] (2013) | Cross-sectional | HCV: 29
Group control: 29 | Minimental
T D.S/S.T/T.T B.N.T/T.F.V; T.D/G.F.D.T G.F.D.T/S.S.T/RAVLT | No difference between the groups | Strict exclusion criterion |
|
| Ibrahim et al. [37]. (2016) | Cross-sectional | HCV: 38
Group control: 210 | Penn cognitive battery—Arabic version | Cognitive change involving various cognitive areas in the HCV group | Potential inclusion of patients with liver cirrhosis |
|
| Hilsabeck et al. [38] (2003) | Cross-sectional | HCV: 21 | B.V.M.T-R/S.S.T/T.T/C.T | Cognitive changes: visuoconstructive, attention/concentration, visual scanning, psychomotor speed, and working memory | Inclusion of HIV patients, use of interferon and psychotropic drugs |
|
| Fontana et al. [39]. (2005) | Cross-sectional | HCV: 201 | T.P-D/T.D T.T | 33% presented dysfunction in the verbal memory and working memory | Inclusion of patients with liver cirrhosis |
|
